Key clinical point: A prospective study suggests patients with concurrent diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma should be considered for inclusion into clinical trials of newly diagnosed DLBCL.
Major finding: After adjustments, patients with concurrent DLBCL and follicular lymphoma (FL) showed similar event-free survival rates to patients with DLBCL alone (Hazard Ratio, 0.95; 95% CI, 0.71-1.27).
Study details: A prospective cohort study of 1,324 patients with DLBCL alone or with concurrent indolent lymphoma.
Disclosures: The study was funded by the National Cancer Institute and the Predolin Foundation. The authors reported having no conflicts of interest related to the study but disclosed financial relationships with several pharmaceutical companies.
Wang Y et al. Blood. 2019 Jul 26. doi: 10.1182/blood.2019000858